Medical Director · Curex
Dr. Chet TharpeMD
Allergy and Immunology · 15+ years in practice
- years in practice
- 15+years in practice
- board certifications
- 2board certifications
- peer-reviewed studies
- 3peer-reviewed studies
Biography
Dr. Chet Tharpe serves as Medical Director at Curex, where he oversees clinical protocols for sublingual immunotherapy and reviews patient treatment plans. He has spent more than 15 years treating allergic rhinitis, asthma, and environmental sensitivities, and is a published voice in the field of at-home allergen immunotherapy. In 2026 he led two peer-reviewed real-world studies of telemedicine-delivered sublingual immunotherapy: an outcomes study of 2,897 patients in Frontiers in Allergy, and a safety study of 13,584 patients across 18,398 patient-years in Allergy, Asthma & Clinical Immunology. Dr. Tharpe is a member of the American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI).
Published research
3 peer-reviewed publications.
Peer-reviewed research · authored
Real-world safety of personalized telemedicine-delivered sublingual immunotherapy: reported adverse events across 18,398 patient-years
Allergy, Asthma & Clinical Immunology · 2026
- 2026Real-world outcomes of personalized sublingual immunotherapy for environmental allergies delivered through a telemedicine platform: a retrospective longitudinal cohort studyFrontiers in Allergy · PMID 42358593
- 2015Pediatric allergic rhinitisImmunology and Allergy Clinics of North America · PMID 25459584